Haemonetics Corporation Insiders Selling Stock May Indicate Bearish Signals

🌥️Trending News

Haemonetics Corporation ($NYSE:HAE) is a global healthcare company that provides various innovative solutions to blood and plasma collectors, hospitals, and donors. The company primarily operates in the United States, Europe, and Asia Pacific regions. Over the past year, the company’s insiders have been actively selling their shares, raising questions among investors who are concerned about the potential bearish signals such a move may indicate. Insider selling can be seen as an indication of waning confidence in the company’s stock by the insiders. It could also signal a change in their sentiment regarding the future prospects of the company. Generally, when insiders start selling large amounts of their stocks, it is often seen as a sign of increasing bearishness – indicating that they believe the stock price could decline in the near future. This could be especially concerning for Haemonetics Corporation as its stock has been declining over the last year.

Additionally, the long-term performance of its stock has been mixed, indicating that investors should be cautious when analyzing its short-term prospects. These facts combined with the increased insider selling could be an ominous sign for potential investors. Overall, it appears that Haemonetics Corporation insiders have been selling their stocks at a rapid rate due to bearish signals in the near-term outlook of the company. This should serve as a warning sign to investors that they should carefully consider the possible risks before entering any long-term positions in this stock.

Market Price

On Thursday, HAEMONETICS CORPORATION stock opened at $87.4 and closed at $88.3, up by 0.7% from last closing price of 87.8. With the recent insider selling, investors are beginning to question the company’s financial health and outlook. Although the stock may have seen a slight increase on Thursday, the insider sales suggest that the long term outlook may not be so positive. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Haemonetics Corporation. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Haemonetics Corporation. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Haemonetics Corporation. More…

Key Ratios Snapshot

Some of the financial key ratios for Haemonetics Corporation are shown below. More…

Analysis

At GoodWhale, we’re dedicated to providing reliable and up-to-date data analysis to our investors. We recently completed a deep dive into HAEMONETICS CORPORATION’s fundamentals. After a comprehensive evaluation, our Risk Rating assigned to HAEMONETICS CORPORATION is considered high risk in terms of financial and business aspects. We uncovered 3 risk warnings for HAEMONETICS CORPORATION based on our analyses of their income sheet, balance sheet, and non-financial performance. To access the full report, feel free to register on goodwhale.com. We’re sure that our data analysis will be useful in helping investors make informed decisions about HAEMONETICS CORPORATION. More…

Peers

The company has a wide range of products, including plasma collection systems, platelet and plasma pheresis systems, and whole blood collection systems. Haemonetics Corp. also provides services related to blood and plasma collection, such as plasma processing and storage, platelet and white blood cell processing, and whole blood processing. The company has a strong presence in the United States, Europe, Asia, and Australia. Merit Medical Systems Inc, Lagis Enterprise Co Ltd, StatSure Diagnostic Systems Inc are some of the major competitors of Haemonetics Corp.

– Merit Medical Systems Inc ($NASDAQ:MMSI)

Medtronic is a medical device company that develops and manufactures a wide range of products, from pacemakers to artificial hearts. The company has a market cap of $3.9 billion and a return on equity of 4.51%. Medtronic’s products are used by millions of people around the world, and the company is a leading provider of medical devices and services.

– Lagis Enterprise Co Ltd ($TPEX:6730)

Lagis Enterprise Co Ltd is a publicly traded company with a market capitalization of 1.02 billion as of 2022. The company has a return on equity of 12.12%. Lagis Enterprise Co Ltd is a diversified holding company that operates in a variety of industries, including construction, real estate, hospitality, and retail. The company has a strong presence in Taiwan and China, and its products and services are also available in North America, Europe, and Asia.

– StatSure Diagnostic Systems Inc ($OTCPK:SSUR)

StatSure Diagnostic Systems Inc is a company that manufactures and sells diagnostic products and services. The company has a market cap of 107.06k as of 2022 and a Return on Equity of 15.2%. The company’s products and services are used by healthcare professionals to diagnose and treat patients.

Summary

Haemonetics Corporation is a medical technology company, and its stock has been of interest to investors recently due to increased insider activity. Over the past year, many Haemonetics insiders have sold large amounts of shares, which may indicate a bearish trend in the stock. Analyzing the performance of the company compared to its peers and understanding the reasons for the insider activity can be beneficial for investors when considering whether to buy or sell shares.

Technical analysis of the stock’s price performance over time can also help inform investors’ decisions. Finally, staying informed on the company’s upcoming news and financial releases can provide insight into the potential future of Haemonetics Corporation stock.